PMID- 8886503
OWN - NLM
STAT- MEDLINE
DCOM- 19970206
LR  - 20190826
IS  - 0305-1870 (Print)
IS  - 0305-1870 (Linking)
VI  - 23
IP  - 8
DP  - 1996 Aug
TI  - Tetrandrine as a calcium antagonist.
PG  - 751-3
AB  - 1. The Ca(2+)-antagonism of tetrandrine (TET) on the Ca2+ mobilization in various 
      types of cells were reviewed. Inositol trisphosphate (IP3)-generating drugs were 
      used as Ca(2+)-mobilizing agonists and the effects were compared with those 
      produced by using the microsomal Ca(2+)-ATPase inhibitor thapsigargin (TG), which 
      is a tool for analysing Ca2+ store-regulated Ca2+ entry (capacitative Ca2+ 
      entry). 2. In rat phaeochromocytoma PC12 cells, 100 mumol/L TET abolished high K+ 
      (30 mmol/L)-induced sustained increases in cytoplasmic Ca2+ concentrations 
      ([Ca2+]i) and partially inhibited bradykinin (1 mumol/L)- or TG (100 
      nmol/L)-induced Ca2+ entry. 3. In NIH/3T3 fibroblasts and rat parotid acinar 
      cells, 100 mumol/L TET abolished Ca2+ entry induced by bombesin (1 mumol/L) and 
      carbachol (100 mumol/L), respectively, or TG (100 nmol/L). However, in the human 
      leukaemia T cell line Jurkat, 100 mumol/L TET did not inhibit Ca2+ entry evoked 
      by either the anti-CD3 antibody OKT3 (10 mg/L) or TG (100 nmol/L). 4. In rat 
      glioma C6 cells, the effects of TET on Ca2+ mobilization were further examined. 
      At a high concentration, TET (300 mumol/L) alone did not affect [Ca2+]i in C6 
      cells. Tetrandrine inhibited the peak and sustained increases in [Ca2+]i induced 
      by bombesin and TG in a dose-dependent manner. Although TET or TG did not produce 
      increases in IP3, TET did inhibit increases in IP3 produced by bombesin. 5. Our 
      results suggest that the action of TET on Ca2+ entry is dependent on cell types 
      and that TET inhibits both Ca2+ entry from the extracellular medium and Ca2+ 
      release from intracellular stores in rat glioma C6 cells.
FAU - Takemura, H
AU  - Takemura H
AD  - Department of Pharmacology, School of Medicine, Sapporo Medical University, 
      Japan.
FAU - Imoto, K
AU  - Imoto K
FAU - Ohshika, H
AU  - Ohshika H
FAU - Kwan, C Y
AU  - Kwan CY
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Alkaloids)
RN  - 0 (Benzylisoquinolines)
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Enzyme Inhibitors)
RN  - 29EX23D5AJ (tetrandrine)
RN  - 67526-95-8 (Thapsigargin)
RN  - S8TIM42R2W (Bradykinin)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Alkaloids/*pharmacology
MH  - Animals
MH  - *Benzylisoquinolines
MH  - Bradykinin/pharmacology
MH  - Calcium/*metabolism
MH  - Calcium Channel Blockers/*pharmacology
MH  - Cell Line
MH  - Enzyme Inhibitors/pharmacology
MH  - PC12 Cells/drug effects
MH  - Rats
MH  - Thapsigargin/antagonists & inhibitors/pharmacology
EDAT- 1996/08/01 00:00
MHDA- 1996/08/01 00:01
CRDT- 1996/08/01 00:00
PHST- 1996/08/01 00:00 [pubmed]
PHST- 1996/08/01 00:01 [medline]
PHST- 1996/08/01 00:00 [entrez]
AID - 10.1111/j.1440-1681.1996.tb01772.x [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 1996 Aug;23(8):751-3. doi: 
      10.1111/j.1440-1681.1996.tb01772.x.